Table 1 Exosomal circRNAs and their function in tumorigenesis
From: Recent advances of exosomal circRNAs in cancer and their potential clinical applications
Tumor type | circRNA | Target molecules | Function | References |
|---|---|---|---|---|
NSCLC | Circ-RACGAP1 | Wnt/β-catenin | Proliferation | [53] |
NSCLC | Circ_0076305 | miR-186-5p/ABCC1 | DDP resistance | [78] |
NSCLC | Circ-VMP1 Circ_0014235 | miR-524-5p/SOX2 miR-520a-5p/CDK4 | DDP resistance | [79] |
NSCLC | Circ-STAB2 | miR-330-5p/PEAK1 | Progression | |
NSCLC | Circ_0007385 | miR-1253/FAM83A | Proliferation, stemness | [94] |
NSCLC | Circ_0008717 | miR-1287-5p/PAK2 | Tumorigenicity | [95] |
NSCLC | Circ-ARHGAP10 | miR-638/FAM83F | Progression | [96] |
NSCLC | Circ_102481 | miR-30a-5p/ROR1 | EGFR-TKIs resistance | [97] |
NSCLC | Circ-PLK1 | miR-1294/HMGA1 | Progression | [98] |
NSCLC | Circ_0014235 | miR-520a-5p/CDK4 | DDP resistance | [99] |
NSCLC | Circ_0002130 | miR-498 | Osimertinib resistance | [100] |
NSCLC | Circ-CCDC134 | miR-625-5p/NFAT5 | Progression | [101] |
Lung cancer | Circ-DNER | miR-139-5p/ITGB8 | Paclitaxel resistance | [102] |
LUAD | CircRAPGEF5 | miR-1236-3p/ZEB1 | Metastasis | [64] |
CRC | Circ-PACRGL | miR-142-3p/miR-506-3p | Metastasis | [62] |
CRC | Circ_0005963 | miR-122 | Oxaliplatin resistance | [84] |
CRC | CircATG4B | Autophagy | Oxaliplatin resistance | [88] |
CRC | Circ_0007334 | miR/KLF12 | Progression | [103] |
CRC | Circ-COG2 | miR-1305/TGF-β2/smad3 | Progression | [104] |
CRC | Circ-FMN2 | miR-338-3p/MSI1 | Progression | [105] |
CRC | CircCOL1A2 | miR-665/LASP1 | Progression | [106] |
CRC | Circ_0005615 | miR-873-5p/FOSL2 | Progression | [107] |
CRC | Circ_0000395 | miR-432-5p/MYH9 | Progression | [108] |
CRC | Circ-TUBGCP4 | miR-146b-3p/PDK/Akt | Metastasis | [109] |
CRC | Circ-PABPC1 | miR-874/microRNA-1929 | Metastasis | [110] |
CRC | Circ-133a | miR-133a/GEF-H1/RhoA | Metastasis | [111] |
HCC | Circ-DB | miR-34a/USP7/Cyclin A2 | Proliferation | [51] |
HCC | Circ-WDR25 | miR-4474-3p/ALOX15 | Proliferation | [52] |
HCC | CircMMP2 | miR-136-5p/MMP2 | Metastasis | [63] |
HCC | Circ_0003028 | miR-498/ODC1 | EMT process | [67] |
HCC | Circ_100338 | Angiogenesis | Metastasis | [69] |
HCC | Circ-Cdr1as | miR-1270 | Progression | [112] |
HCC | Circ-TTLL5 | miR-136-5p/KIAA1522 | Metastasis | [113] |
HCC | Circ-SORE | YBX1 | Sorafenib resistance | [114] |
HCC | Circ-PAK1 | YAP | Lenvatinib resistance | [115] |
HCC | Circ-ZFR | STAT3/NF-κB pathway | DDP resistance | [116] |
Breast cancer | Circ-SERPINE2 | / | Proliferation | [48] |
Breast cancer | CircPSMA1 | miR-637/Akt1/β-catenin | Metastasis | [65] |
Breast cancer | Circ-MMP11 | miR-153-3P/ANLN | Lapatinib resistance | [117] |
Breast cancer | CCirc-UBE2D2 | miR-200a-3p | Tamoxifen resistance | [118] |
Breast cancer | Circ-CARM1 | miR-1252-5p/PFKFB2 | Glycolysis, progression | [119] |
Breast cancer | Circ-EGFR | miR-1299/EGFR | Pirarubicin resistance | [120] |
Gastric cancer | Circ-PRRX1 | miR-596 | Proliferation | [47] |
Gastric cancer | Circ_0044366 | / | Metastasis | [70] |
Gastric cancer | Circ_0091741 | miR-330-3p/ TRIM14 | Oxaliplatin resistance | [85] |
Gastric cancer | Circ-NRIP1 | miR-145-5p/AKT1/mTOR | Metastasis | [121] |
Gastric cancer | Circ_0001789 | miR-140-3p/PAK2 | Progression | [122] |
Gastric cancer | Circ_0063562 | miR-449a/SHMT2 | DDP resistance | [123] |
Gastric cancer | Circ-PVT1 | miR-301-5p/YAP1 | DDP resistance | [124] |
Gastric cancer | Circ-LDLRAD3 | miR-588/SOX5 | DDP resistance | [125] |
Gastric cancer | Circ_0032821 | miR-515-5p/SOX9 | Oxaliplatin resistance | [126] |
Glioma | Circ_0072083 | miR-1252-5p/NANOG | TMZ resistance | [81] |
Glioma | Circ-WDR62 | miR-370-3p/MGMT | TMZ resistance | [127] |
Glioma | Circ-GLS3 | miR − 548 m/MED31 | TMZ resistance | [128] |
Glioma | Circ_0043949 | miR-876-3p/ITGA1 | TMZ resistance | [129] |
Glioblastoma | Circ-AHCY | miR-1294/ Wnt/β-catenin | Proliferation | [130] |
Glioblastoma | Circ_0012381 | miR-340-5p/CCL2/CCR2 | Proliferation | [131] |
Glioblastoma | Circ-KIF18A | FOXC2/PI3K/AKT | Angiogenesis | [132] |
Prostate cancer | Circ_0081234 | / | EMT process | [66] |
Prostate cancer | Circ-SFMBT2 | miR-136-5p/TRIB1 | Docetaxel resistance | [86] |
Prostate cancer | Circ-XIAP | miR-1182/TDP52 | Docetaxel resistance | [87] |
Prostate cancer | Circ-KDM4A | miR-338-3p/CUL4B | Malignancy | [133] |
Ovarian cancer | Circ-NFIX | miR-518a-3p/TRIM44 | Angiogenesis | [71] |
Ovarian cancer | Circ-PIP5K1A | miR-942/NFIB | DDP resistance | [134] |
Ovarian cancer | Circ-Foxp1 | miR-22/miR-150-3p | DDP resistance | [135] |
Ovarian cancer | Circ_0007841 | miR-532-5p/NFIB | DDP resistance | [136] |
PCa | Circ-PDK1 | miR-628-3p/BPTF/c-Myc | Proliferation | [46] |
PCa | Circ-ZNF91 | miR-23b-3p/SIRT1 | Gemcitabine resistance | [82] |
PCa | Circ-IARS | miR-122 | Metastasis | [137] |
EC | Circ_0000337 | miR-337-3p | DDP resistance | [138] |
CCA | Circ_0020256 | miR-432-5p/E2F3 | Proliferation | [49] |
RCC | Circ-PRKCI | miR-545-3p/CCND1 | Proliferation | [50] |
MM | Circ-HNRNPU | / | Proliferation | [54] |
PTC | Circ_007293 | miR-653-5p/PAX6 | EMT process | [68] |
ESCC | Circ_0026611 | / | LNM | [72] |
Osteosarcoma | Circ_103801 | / | DDP resistance | [80] |
Neuroblastoma | Circ-DLGAP4 | miR-143-HK2 | Doxorubicin resistance | [83] |
Cervical cancer | Circ_0074269 | miR-485-5p/TUFT1 | DDP resistance | [139] |
Melanoma | Circ_0001005 | miRs sponges | Vemurafenib resistance | [140] |
NPC | Circ-PARD3 | miR-579-3p/SIRT1 | Cisplatin resistance | [141] |
CCA | Circ-CCAC1 | EZH2 | Angiogenesis | [142] |